Parkwood LLC Immuno Gen, Inc. Transaction History

Parkwood LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $321,791 - $773,488	25,826 New	25,826 $766,000
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $232,960 - $336,440	52,000 New	52,000 $249,000
Q2 2022 Aug 15, 2022	SELL	$3.15 - $5.76 $243,283 - $444,862	-77,233 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$4.26 - $7.48 $329,012 - $577,702	77,233 New	77,233 $368,000
Q3 2021 Nov 12, 2021	SELL	$5.02 - $6.59 $325,918 - $427,849	-64,924 Closed	0 $0

Q2 2021 Aug 13, 2021	BUY	$5.79 - $8.6 $375,909 - $558,346	64,924 New	64,924 $428,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Parkwood LLC, based on Form 13F filings with the SEC.

Stay updated on Parkwood LLC with notifications on news.